I have many patients that have a condition called empty sella syndrome. It can sound scary, but is more common than expected in the general population about 39% of people have this and most often causes little symptoms other than headaches and some hormone disruption. However, there are some key risks. Thus I wanted to do a blog post to help the families understand what needs to be followed long-term.
When they come to see the ophthalmologist/eye doctor/eye surgeon their primary doctor is asking for us to look for papilledema and any visual field defect. Most of our patients are asymptomatic meaning they don’t have symptoms of vision changes or swelling of their optic nerve. And while vision loss is rare in these patients, that is the most dreaded fear of empty sella syndrome So with the help of open evidence and some putting together of references, I put together this explanation below.
What Is Empty Sella Syndrome?
Empty sella syndrome (ESS) is a condition characterized by the herniation of cerebrospinal fluid (CSF) into the sella turcica—the bony cavity at the base of the skull that houses the pituitary gland. This herniation occurs through an incompetent or defective sellar diaphragm, causing the pituitary gland to become flattened or compressed against the floor of the sella. On imaging studies, the sella appears "empty" because it is filled with CSF rather than normal pituitary tissue.[1][2]
Empty sella can be classified as primary or secondary. Primary empty sella (PES) occurs spontaneously without an identifiable cause, often related to a congenital defect in the sellar diaphragm combined with factors such as intracranial hypertension or changes in pituitary volume.[1] Secondary empty sella results from identifiable causes including pituitary surgery, radiation therapy, tumor infarction, or traumatic brain injury.[3][2]
The condition is remarkably common—incidental radiographic findings of empty sella are present in up to 35% of the general population.[2] However, most individuals with an empty sella remain asymptomatic. The term "empty sella syndrome" is reserved for patients who develop clinical manifestations, including endocrine dysfunction, neurological symptoms, or ophthalmologic complications.[1][2]
Pathophysiology: Understanding the Mechanism
The pathophysiology of primary empty sella involves multiple factors. The sellar diaphragm normally acts as a barrier between the subarachnoid space and the pituitary fossa. When this diaphragm is incompetent—either congenitally or acquired—CSF can herniate into the sella.[1] This process is often facilitated by chronically elevated intracranial pressure, which may be associated with conditions such as idiopathic intracranial hypertension (IIH), obesity, hypertension, and multiple pregnancies.[1][4][5]
The relationship between empty sella and intracranial hypertension is bidirectional. Chronic intracranial hypertension can cause empty sella formation through persistent CSF pulsations that gradually enlarge the sella and compress the pituitary gland.[6] Conversely, empty sella is frequently observed as a radiographic sign in patients with IIH, though its presence alone does not confirm elevated intracranial pressure.[5][7]
Recent research has demonstrated that the pituitary-to-sella turcica ratio correlates significantly with the severity of transverse sinus stenosis and brain volume changes in IIH patients, suggesting that both findings reflect CSF and interstitial fluid dyshomeostasis.[8] The degree of pituitary compression appears related to the extent of CSF filling: partial empty sella involves less than 50% CSF filling with pituitary thickness greater than 2 mm, while complete empty sella shows 50% or greater filling with pituitary thickness less than 2 mm.[9]
Vision and Optic Nerve Health: Critical Considerations
Visual Complications
Visual disturbances represent one of the most concerning manifestations of empty sella syndrome, occurring in approximately 8-28% of patients depending on the study population.[4][5] The ophthalmologic complications can range from mild visual complaints to severe vision-threatening conditions.[1]
The primary mechanisms of visual impairment in ESS include:
1. Papilledema: Optic disc swelling from elevated intracranial pressure, which can lead to permanent vision loss if untreated.[1][6]
2. Chiasmal herniation: In severe cases, the optic chiasm and suprasellar visual system can herniate into the empty sella, causing compression and visual field defects.[10][11]
3. Associated intracranial hypertension: When empty sella occurs with IIH, patients face a higher risk of visual field defects and vision loss compared to either condition alone.[6]
Risk of Permanent Vision Loss
The risk of permanent vision loss in empty sella syndrome depends primarily on whether the patient has associated intracranial hypertension with papilledema. Patients with undiagnosed papilledema are at significant risk of irreversible vision loss.[7] However, visual disturbances may be absent or minimal even when herniation of the suprasellar visual system is present, and progression of visual symptoms is not inevitable.[11]
Importantly, there is no direct correlation between the severity of visual symptoms and the degree of herniation of the visual structures in either primary or secondary empty sella.[11] This means that patients can have significant anatomical changes without corresponding visual complaints, emphasizing the need for objective ophthalmologic assessment rather than relying solely on symptoms.
Optic Nerve Monitoring
For patients with empty sella syndrome, particularly those with visual complaints, headaches, or evidence of intracranial hypertension, comprehensive ophthalmologic evaluation is essential. This should include:
- Fundoscopic examination to detect papilledema
- Visual acuity testing
- Visual field testing (perimetry) to identify field defects, particularly bitemporal defects suggestive of chiasmal involvement
- Optical coherence tomography (OCT) to assess retinal nerve fiber layer thickness
Patients with IIH and empty sella who have visual complaints or papilledema should undergo visual field testing at baseline and regular intervals during follow-up. While specific guidelines for visual field testing frequency in isolated empty sella are not well-established, patients with symptoms or risk factors for intracranial hypertension warrant closer monitoring—typically every 3-6 months initially, then annually if stable.[1][2]
Diagnosis: Imaging and Clinical Evaluation
Imaging Modalities
Magnetic resonance imaging (MRI) is the gold standard for diagnosing empty sella.[2][12] High-resolution pituitary protocols with thin-section imaging can accurately characterize the anatomy of the pituitary gland, infundibulum, optic chiasm, and vascular structures. MRI clearly demonstrates CSF filling the sella and can distinguish between partial and complete empty sella.[12]
Key MRI findings include:
- CSF signal intensity filling the sella turcica
- Flattened or compressed pituitary gland against the sellar floor
- Possible deviation of the pituitary stalk
- Assessment of suprasellar structures for herniation
Contrast enhancement is not typically required for diagnosis but may be useful for surgical planning or to exclude other sellar lesions.[12]
Computed tomography (CT) can also identify empty sella but is inferior to MRI in defining the relationship between the pituitary gland and surrounding structures.[11][12]
Clinical Evaluation
The diagnosis of empty sella syndrome requires both radiographic findings and clinical manifestations. Comprehensive evaluation should include:
1. Detailed history: Headaches, visual changes, menstrual irregularities, symptoms of hormone deficiency, history of multiple pregnancies, obesity, hypertension[1][4]
2. Neurological examination: Assessment for signs of intracranial hypertension
3. Ophthalmologic examination: Fundoscopy, visual fields, visual acuity[1]
4. Endocrine evaluation: Comprehensive pituitary function testing (detailed below)[2]
Distinguishing Clinically Significant Empty Sella
Not all empty sella findings require extensive workup. Clinical and imaging features that suggest clinically significant empty sella (associated with intracranial hypertension) include younger age, headaches, visual complaints, obesity, and the presence of multiple MRI signs of intracranial hypertension such as optic nerve tortuosity, increased perioptic CSF, and transverse sinus stenosis.[5]
Endocrine Complications and Hormonal Assessment
Prevalence of Hypopituitarism
Pituitary hormone deficiencies are common in empty sella syndrome, though prevalence estimates vary widely. Large cohort studies report hypopituitarism in 34-40% of patients with primary empty sella and up to 64% of those with secondary empty sella.[13][14]
The most frequently affected hormonal axes include:
- Hypogonadism: 20-26% of patients[13][14]
- Growth hormone deficiency: 15% of patients[14]
- Adrenal insufficiency: 15% in primary empty sella, 55% in secondary empty sella[13][14]
- Hypothyroidism: 10% of patients[14]
- Hyperprolactinemia: 7-12% of patients (typically mild elevation 50 ng/mL)[3][4][14]
- Diabetes insipidus: 1.5% of patients[14]
Importantly, hormonal alterations are found in approximately 29% of patients with incidentally discovered empty sella, highlighting the need for endocrine evaluation even in asymptomatic individuals.[14]
Risk Factors for Hypopituitarism
Several factors increase the risk of pituitary dysfunction in empty sella:
- Male sex: Men have higher rates of hypopituitarism than women[14]
- Complete vs. partial empty sella: Complete empty sella (≥50% CSF filling) is associated with significantly higher rates of adrenal insufficiency and hypogonadism[9]
- Secondary empty sella: Higher risk than primary empty sella[13]
- History of traumatic brain injury[14]
- Progression from partial to complete empty sella on serial imaging[14]
Recommended Hormonal Testing
All patients diagnosed with empty sella should undergo comprehensive pituitary function testing, regardless of symptoms.[2][15][9] The recommended baseline evaluation includes:
- Morning cortisol and ACTH (consider dynamic testing if borderline)
- Free thyroxine (fT4) and TSH
- Testosterone (men) or estradiol (women), FSH, and LH
- Prolactin
- IGF-1 (as a screening test for growth hormone deficiency)
Dynamic stimulation tests (such as insulin tolerance test, ACTH stimulation test, or GnRH stimulation test) may be necessary when basal testing suggests deficiency.[2][13]
Standard of Care: Monitoring and Follow-Up
Initial Assessment
Upon diagnosis of empty sella, patients should undergo:
1. Comprehensive endocrine evaluation as outlined above
2. Ophthalmologic examination including fundoscopy and visual fields
3. Neurological assessment for signs of intracranial hypertension
4. MRI with dedicated pituitary protocol
Long-Term Follow-Up Strategy
The natural history of empty sella syndrome is generally benign, with hormonal deterioration occurring in only about 3% of patients during long-term follow-up.[14] Based on recent longitudinal studies, the following approach is recommended:
For patients with normal pituitary function at diagnosis:
- The risk of developing new hormone deficiencies is low (approximately 1-3% over 5 years)[13][14]
- Regular endocrine follow-up is not routinely necessary unless symptoms develop[13]
- Clinical monitoring for symptoms of hormone deficiency is appropriate
For patients with documented hypopituitarism:
- Appropriate hormone replacement therapy as directed by endocrinology
- Periodic reassessment of hormone levels to optimize replacement
- Some patients (8%) may experience hormonal recovery, warranting periodic re-evaluation[14]
For patients with visual symptoms or intracranial hypertension:
- Regular ophthalmologic follow-up with visual field testing
- Frequency depends on severity: every 3-6 months if symptomatic or with papilledema, annually if stable
- Multidisciplinary care involving neurology, ophthalmology, and endocrinology[1][2]
Imaging follow-up:
- Repeat MRI is not routinely necessary unless clinical deterioration occurs
- Progression from partial to complete empty sella is the only imaging parameter associated with hormonal deterioration[14]
- Consider repeat imaging if new symptoms develop
Systemic Health Implications
Cardiovascular and Metabolic Health
Empty sella syndrome is frequently associated with obesity (present in approximately 50% of patients), hypertension (27%), and metabolic syndrome.[4][16] These associations may reflect shared pathophysiologic mechanisms, particularly related to intracranial pressure dysregulation. Patients should receive appropriate screening and management for cardiovascular risk factors.
Neurological Manifestations
Headaches are the most common neurological symptom, occurring in 33-59% of patients with empty sella.[4][16] The headaches may be related to intracranial hypertension, hormonal imbalances, or other mechanisms. When empty sella coexists with IIH, headache prevalence increases to over 90%.[5]
Other neurological complications can include:
- Cerebrospinal fluid rhinorrhea (CSF leak through the nose)[1]
- Vestibular disturbances and hearing loss[17]
- In rare cases, herniation of cerebral arteries into the sella[10]
Mental Health and Quality of Life
While specific data on mental health outcomes in empty sella syndrome are limited, the condition shares clinical features with fibromyalgia and chronic fatigue syndrome, including fatigue, pain, and HPA axis dysfunction.[17] Patients with untreated hormone deficiencies, particularly growth hormone and cortisol deficiency, may experience fatigue, depression, and reduced quality of life. Appropriate hormone replacement can significantly improve these symptoms.
The psychological impact of chronic headaches, visual disturbances, and the diagnosis itself should not be underestimated. Multidisciplinary care that addresses both physical and psychological aspects is important for optimal outcomes.
Prognosis and Life Expectancy
The overall prognosis for patients with empty sella syndrome is excellent. The condition itself does not reduce life expectancy when appropriately managed.[14] Key prognostic considerations include:
Favorable prognostic factors:
- Most patients remain stable over long-term follow-up
- Hormonal deterioration is uncommon (3% over median 58 months)[14]
- Many patients with incidental empty sella remain asymptomatic throughout life
- Appropriate hormone replacement normalizes life expectancy for those with hypopituitarism
Potential complications requiring vigilance:
- Permanent vision loss from untreated papilledema and intracranial hypertension
- Adrenal crisis in patients with unrecognized adrenal insufficiency
- Cardiovascular complications from untreated hormone deficiencies or metabolic syndrome
With appropriate initial evaluation, hormone replacement when indicated, and monitoring for visual complications, patients with empty sella syndrome can expect normal longevity and quality of life.
Treatment Approaches
Hormone Replacement Therapy
Patients with documented hormone deficiencies require targeted replacement:
- Adrenal insufficiency: Hydrocortisone or other glucocorticoid replacement
- Hypothyroidism: Levothyroxine
- Hypogonadism: Testosterone (men) or estrogen/progesterone (women)
- Growth hormone deficiency: Recombinant growth hormone (in selected patients)
Replacement should follow standard endocrine guidelines and be individualized to patient needs.[2]
Management of Intracranial Hypertension
When empty sella is associated with symptomatic intracranial hypertension:
- Weight loss (if obese)
- Acetazolamide or other carbonic anhydrase inhibitors
- Serial lumbar punctures in selected cases
- CSF shunting procedures for refractory cases[16]
Surgical Intervention
Surgery is rarely required but may be indicated for:
- Severe chiasmal herniation with progressive vision loss[10][18]
- CSF rhinorrhea requiring sellar floor repair
- Symptomatic intracranial hypertension refractory to medical management
Surgical techniques include endoscopic endonasal approaches for chiasmapexy (elevation of the herniated chiasm) or sellar floor reconstruction.[18]
Conclusion
Empty sella syndrome represents a spectrum from an incidental radiographic finding to a clinically significant condition requiring multidisciplinary management. While most patients remain asymptomatic, a substantial minority develop endocrine dysfunction or neuro-ophthalmologic complications. Comprehensive initial evaluation with endocrine testing and ophthalmologic examination is essential for all patients. Long-term prognosis is excellent with appropriate management, and regular follow-up can be tailored based on initial findings, with intensive monitoring reserved for those with documented abnormalities.
The comprehensive blog post above provides an evidence-based overview of empty sella syndrome with particular attention to vision health, optic nerve monitoring, endocrine complications, and long-term management strategies. The information is drawn from recent peer-reviewed literature and clinical guidelines.
Key takeaways for clinical practice include the high prevalence of hormonal abnormalities (34-40% in primary empty sella), the importance of baseline comprehensive pituitary testing even in asymptomatic patients, and the reassuring finding that hormonal deterioration is uncommon (only 3%) during long-term follow-up in those with initially normal function.[13][14] For vision monitoring, the critical distinction is between patients with isolated empty sella (generally low risk) versus those with associated intracranial hypertension and papilledema (high risk for permanent vision loss requiring close ophthalmologic surveillance).[7][6]
The evidence supports a risk-stratified approach to follow-up rather than routine intensive monitoring for all patients, which optimizes resource utilization while ensuring appropriate care for those at highest risk of complications.[13][14]
References
1. DIAGNOSIS OF ENDOCRINE DISEASE: Primary Empty Sella: A Comprehensive Review. Chiloiro S, Giampietro A, Bianchi A, et al. European Journal of Endocrinology. 2017;177(6):R275-R285. doi:10.1530/EJE-17-0505.
2. A Comprehensive Review of Empty Sella and Empty Sella Syndrome. Lundholm MD, Yogi-Morren D. Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2024;30(5):497-502. doi:10.1016/j.eprac.2024.03.004.
3. Hypopituitarism. Vance ML. The New England Journal of Medicine. 1994;330(23):1651-62. doi:10.1056/NEJM199406093302306.
4. Primary Empty Sella (PES): A Review of 175 Cases. Guitelman M, Garcia Basavilbaso N, Vitale M, et al. Pituitary. 2013;16(2):270-4. doi:10.1007/s11102-012-0416-6.
5. Factors Determining the Clinical Significance of an "Empty" Sella Turcica. Saindane AM, Lim PP, Aiken A, Chen Z, Hudgins PA. AJR. American Journal of Roentgenology. 2013;200(5):1125-31. doi:10.2214/AJR.12.9013.
6. Does Pseudotumor Cerebri Cause the Empty Sella Syndrome?. Foley KM, Posner JB. Neurology. 1975;25(6):565-9. doi:10.1212/wnl.25.6.565.
7. Prevalence of Incidentally Detected Signs of Intracranial Hypertension on Magnetic Resonance Imaging and Their Association With Papilledema. Chen BS, Meyer BI, Saindane AM, et al. JAMA Neurology. 2021;78(6):718-725. doi:10.1001/jamaneurol.2021.0710.
8. MRI Evaluation of Pituitary/Sella Turcica Ratio and Venoglymphatic Congestion in Idiopathic Intracranial Hypertension. Finkelstein AJ, Schartz D, Mendoza-Ayus S, Bender MT. Neurosurgical Focus. 2026;60(1):E6. doi:10.3171/2025.10.FOCUS25801.
9. Endocrinological Differences Between Partial and Complete Primary Empty Sella: A Comparative Analysis. Akcura C, Guney SC, Alkan S, et al. Neuro Endocrinology Letters. 2025;46(2):86-90.
10. Visual Deterioration and Herniation of the Anterior Cerebral Artery: Unusual Presentation of an Empty Sella Syndrome Complicating Decompression of a Rathke Cleft Cyst. Sivaraju L, Thakar S, Hegde AS. Journal of Neuro-Ophthalmology : The Official Journal of the North American Neuro-Ophthalmology Society. 2016;36(2):156-8. doi:10.1097/WNO.0000000000000348.
11. Herniation of the Suprasellar Visual System and Third Ventricle Into Empty Sellae: Morphologic and Clinical Considerations. Kaufman B, Tomsak RL, Kaufman BA, et al. AJR. American Journal of Roentgenology. 1989;152(3):597-608. doi:10.2214/ajr.152.3.597.
12. ACR Appropriateness Criteria Neuroendocrine Imaging. Burns J, Policeni B, Bykowski J, et al. Journal of the American College of Radiology : JACR. 2019;16(5S):S161-S173. doi:10.1016/j.jacr.2019.02.017.
13. Pituitary Function in Patients With Primary and Secondary Empty Sella. Steckel L, Gizewski ER, Kaser S. Frontiers in Endocrinology. 2025;16:1632824. doi:10.3389/fendo.2025.1632824.
14. A Multicenter Cohort Study in Patients With Primary Empty Sella: Hormonal and Neuroradiological Features Over a Long Follow-Up. Carosi G, Brunetti A, Mangone A, et al. Frontiers in Endocrinology. 2022;13:925378. doi:10.3389/fendo.2022.925378.
15. Primary Empty Sella Syndrome and the Prevalence of Hormonal Dysregulation. Auer MK, Stieg MR, Crispin A, et al. Deutsches Arzteblatt International. 2018;115(7):99-105. doi:10.3238/arztebl.2018.0099.
16. Primary Empty Sella. De Marinis L, Bonadonna S, Bianchi A, Maira G, Giustina A. The Journal of Clinical Endocrinology and Metabolism. 2005;90(9):5471-7. doi:10.1210/jc.2005-0288.
17. The Link Between Empty Sella Syndrome, Fibromyalgia, and Chronic Fatigue Syndrome: The Role of Increased Cerebrospinal Fluid Pressure. Hulens M, Dankaerts W, Rasschaert R, et al. Journal of Pain Research. 2023;16:205-219. doi:10.2147/JPR.S394321.
18. Endonasal Endoscopic Transsphenoidal Chiasmapexy Using a Clival Cranial Base Cranioplasty for Visual Loss From Massive Empty Sella Following Macroprolactinoma Treatment With Bromocriptine: Case Report. Alvarez Berastegui GR, Raza SM, Anand VK, Schwartz TH. Journal of Neurosurgery. 2016;124(4):1025-31. doi:10.3171/2015.2.JNS142015.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.